Evidence map›Paper›PMID 25093396›Full record

Trial reportNature communications2014

Neuroplasticity-based computerized cognitive remediation for treatment-resistant geriatric depression.

Sarah Shizuko Morimoto, Bruce E Wexler, Jiacheng Liu, Willie Hu, Joanna Seirup, George S Alexopoulos

Open access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Remission is insufficient: predictors and mechanistic models of recurrence in late-life depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Late Life Depression: The Essentials and the Essential Distinctions.Focus (American Psychiatric Publishing) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Sarah Shizuko MorimotoWeill Cornell Medical College, Institute of Geriatric Psychiatry, New York, New York 10605, USA.
Bruce E WexlerDepartment of Psychiatry, Yale Medical School, New Haven, Connecticut 06519, USA.
Jiacheng Liu1] Department of Psychiatry, Yale Medical School, New Haven, Connecticut 06519, USA [2] Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, China.
Willie HuWeill Cornell Medical College, Institute of Geriatric Psychiatry, New York, New York 10605, USA.
Joanna SeirupWeill Cornell Medical College, Institute of Geriatric Psychiatry, New York, New York 10605, USA.
George S AlexopoulosWeill Cornell Medical College, Institute of Geriatric Psychiatry, New York, New York 10605, USA.
Cornell University · USYale University · US

Funding

Cornell ACISR for Late Life DepressionP30MH068638 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI ALEXOPOULOS, GEORGE S · 2003 to 2007
$6.5M
Computerized Cognitive Remediation in Geriatric DepressionK23MH095830 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI MORIMOTO, SARAH SHIZUKO · 2012 to 2016
$749k
NIA NIH HHS L30 AG040834NIMH NIH HHS K23 MH095830NIMH NIH HHS P30 MH068638
6 · The paper itself

Abstract

Executive dysfunction (ED) in geriatric depression (GD) is common, predicts poor clinical outcomes and often persists despite remission of symptoms. Here we develop a neuroplasticity-based computerized cognitive remediation-geriatric depression treatment (nCCR-GD) to target ED in GD. Our assumption is that remediation of these deficits may modulate the underlying brain network abnormalities shared by ED and depression. We compare nCCR-GD to a gold-standard treatment (escitalopram: 20 mg per 12 weeks) in 11 treatment-resistant older adults with major depression; and 33 matched historical controls. We find that 91% of participants complete nCCR-GD. nCCR-GD is equally as effective at reducing depressive symptoms as escitalopram but does so in 4 weeks instead of 12. In addition, nCCR-GD improves measures of executive function more than the escitalopram. We conclude that nCCR-GD may be equally effective as escitalopram in treating GD. In addition, nCCR-GD participants showed greater improvement in executive functions than historical controls treated with escitalopram.

Indexed as

Neuronal PlasticityAgedAged, 80 and overAntidepressive Agents, Second-GenerationCase-Control StudiesCitalopramCognitionCognitive Behavioral TherapyDepressionExecutive FunctionFemaleGeriatricsHumansMajor Depressive DisorderMaleMiddle AgedAntidepressive Agents, Second-GenerationCitalopram

Identifiers

PMID25093396
PMCPMC4139707
OpenAlexW2068566265

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.